联合熊去氧胆酸治疗胆汁反流性胃炎的疗效分析

Analysis of Curative Effect of Combined Ursodeoxycholic Acid on Bile Reflux Gastritis

目的观察熊去氧胆酸治疗胆汁反流性胃炎的临床效果。方法抽取2018年6月—2019年6月在该院接受治疗的胆汁反流性胃炎患者78例为研究对象,根据其住院先后顺序从1~78编号,再按等差数列首项为1,公差为2的方式将78例患者平均分为两组,即对照组与实验组,每组39例。对照组采用莫沙必利联合铝碳酸镁咀嚼片治疗,实验组在对照组基础上行熊去氧胆酸治疗,对比两组患者治疗效果,两组患者症状积分变化情况。结果实验组患者治疗总有效率94.87%明显高于对照组79.49%,差异有统计学意义(χ^2=4.278,P<0.05);治疗前两组患者腹痛、腹胀嗳气、恶心呕吐、口干口苦积分差异无统计学意义(P>0.05),治疗后实验组患者腹痛、腹胀嗳气、恶心呕吐、口干口苦积分(0.4±0.2)分、(0.7±0.2)分、(0.6±0.2)分、(1.2±0.4)分均低于对照组(0.9±0.1)分、(1.1±0.3)分、(1.1±0.1)分、(1.8±0.3)分,差异有统计学意义(t=11.254、11.945、11.275、12.575,P<0.05)。结论在莫沙必利、铝碳酸镁咀嚼片的基础上联合熊去氧胆酸治疗胆汁反流性胃炎效果显著,能够进一步提升治疗效果,降低患者各种症状积分。

Objective To observe the clinical effect of ursodeoxycholic acid on bile reflux gastritis.Methods A total of 78 patients with bile reflux gastritis who were treated in the hospital from June 2018 to June 2019 were selected as the research subjects.They were numbered from 1 to 78 according to the order of hospitalization,and the first item was 1 according to the arithmetic difference.The 78 patients were divided into two groups on average with a tolerance of 2,namely the control group and the experimental group.Each group had 39 patients.The control group was treated with mosapride combined with aluminum magnesium carbonate chewable tablets,and the experimental group was treated with ursodeoxycholic acid on the basis of the control group.The treatment effect of the two groups of patients was compared,and the changes in the symptom scores of the two groups of patients.Results The total effective rate of treatment in the experimental group was 94.87%,which was significantly higher than that in the control group,79.49%,the difference was statistically significant(χ^2=4.278,P<0.05);before treatment,the two groups of patients had abdominal pain,bloating,belching,nausea and vomiting,dry mouth and mouth pain score had not statistically significant(P>0.05),after treatment,the patients in the experimental group had abdominal pain,bloating,belching,nausea and vomiting,dry mouth and mouth pain scores of(0.4±0.2)points,(0.7±0.2)points,(0.6±0.2)points,(1.2±0.4)points,which were lower than those of the control group(0.9±0.1)points,(1.1±0.3)points,(1.1±0.1)points,(1.8±0.3)points(t=11.254,11.945,11.275,12.575,P<0.05),the difference was statistically significant.Conclusion The combination of mosapride and aluminum magnesium carbonate chewable tablets combined with ursodeoxycholic acid in the treatment of bile reflux gastritis has a significant effect,which can further improve the therapeutic effect and reduce the score of various symptoms in patients.